^
    Back
    Association details:
    Biomarker:EGFR mutation + CREBBP mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:cisplatin (DNA synthesis inhibitor) +
    vinorelbine tartrate (Tubulin polymerization inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: B - Late Trials
    New
    Source:
    ASCO 2023
    Title:

    Predictive value of co-existing genetic alterations and tumor mutation burden for patients with completely resected non-small cell lung cancer harboring EGFR mutation: Biomarker analysis of phase III IMPACT study.

    Published date:
    05/25/2023
    Excerpt:
    This IMPACT-TR study is an exploratory biomarker study for completely resected, EGFR-mutated NSCLC patients who received gefitinib or cisplatin plus vinorelbine (cis/vin) in a phase III IMPACT study (Trial registration number: UMIN000044738....In the cis/vin group, patients with CREBBP mutation had significantly shorter DFS (HR 2.70, 95%CI 1.05-6.97, p=0.040)…
    DOI:
    10.1200/JCO.2023.41.16_suppl.8524